{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:54:13Z","timestamp":1792662853056,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xjidi.2024.100258","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T02:15:19Z","timestamp":1705371319000},"page":"100258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5103-0842","authenticated-orcid":false,"given":"Julia","family":"Tietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-622X","authenticated-orcid":false,"given":"Tea","family":"Gunde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6872-8805","authenticated-orcid":false,"given":"Stefan","family":"Warmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-9458","authenticated-orcid":false,"given":"Christopher","family":"Weinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6445-0631","authenticated-orcid":false,"given":"Matthias","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3022-8974","authenticated-orcid":false,"given":"Alexandre","family":"Simonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4556-6288","authenticated-orcid":false,"given":"Christian","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3106-1629","authenticated-orcid":false,"given":"Maria","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-3141","authenticated-orcid":false,"given":"Fabio","family":"Spiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3231-4639","authenticated-orcid":false,"given":"Simone","family":"Muntwiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1207-105X","authenticated-orcid":false,"given":"Belinda","family":"Wickihalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2944-3040","authenticated-orcid":false,"given":"Dana","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3215-8018","authenticated-orcid":false,"given":"Dania","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6009-4163","authenticated-orcid":false,"given":"Julia","family":"Zeberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7017-538X","authenticated-orcid":false,"given":"Robin","family":"Heiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3475-7543","authenticated-orcid":false,"given":"Naomi","family":"Fl\u00fcckiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6206-424X","authenticated-orcid":false,"given":"Noriko","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7038-5670","authenticated-orcid":false,"given":"Yoshihide","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-301X","authenticated-orcid":false,"given":"Nobuaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-2415","authenticated-orcid":false,"given":"Markus","family":"Fehrholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5927-6998","authenticated-orcid":false,"given":"Marta","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3441-0553","authenticated-orcid":false,"given":"Peter","family":"Lichtlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2167-7440","authenticated-orcid":false,"given":"David","family":"Urech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0107-4821","authenticated-orcid":false,"given":"Daniel","family":"Snell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100258_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Atopic dermatitis","volume":"22","author":"Bieber","year":"2010","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100258_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw2938","article-title":"A\u00a0key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis","volume":"5","author":"Bitton","year":"2020","journal-title":"Sci Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty AD Chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100258_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A\u00a0sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nbt0297-159","article-title":"Design and production of novel tetravalent bispecific antibodies","volume":"15","author":"Coloma","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.xjidi.2024.100258_bib8","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \"itchy\" cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2024.100258_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12349","article-title":"Human IgG4: a structural perspective","volume":"268","author":"Davies","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.xjidi.2024.100258_bib10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.179.1.135","article-title":"Interleukin 13 is a B cell stimulating factor","volume":"179","author":"Defrance","year":"1994","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.xjidi.2024.100258_bib12","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamadermatol.2023.2609","article-title":"Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab","volume":"159","author":"Deng","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100258_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/19420862.2016.1248012","article-title":"Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments","volume":"9","author":"Egan","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.xjidi.2024.100258_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12920-015-0133-x","article-title":"Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways","volume":"8","author":"Ewald","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.xjidi.2024.100258_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227817","article-title":"Tissue-resident macrophages can be generated de novo in adult human skin from resident progenitor cells during substance P-mediated neurogenic inflammation ex\u00a0vivo","volume":"15","author":"Gherardini","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2024.100258_bib18","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2021-1-7","article-title":"Selective IL-13 inhibitors for the treatment of atopic dermatitis","volume":"10","author":"Gon\u00e7alves","year":"2021","journal-title":"Drugs Context"},{"key":"10.1016\/j.xjidi.2024.100258_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaci.2003.12.007","article-title":"Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis","volume":"113","author":"Hijnen","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-2567.2007.02668.x","article-title":"Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response","volume":"122","author":"Ip","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.xjidi.2024.100258_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1398-9995.2005.00774.x","article-title":"Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis","volume":"60","author":"Jahnz-Rozyk","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2024.100258_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1067\/mai.2001.113237","article-title":"Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity","volume":"107","author":"Kakinuma","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib25","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1111\/all.15635","article-title":"Autologous Th2-polarized lymphocytes induce atopic dermatitis lesions in non-atopic human skin xenotransplants","volume":"78","author":"Keren","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.xjidi.2024.100258_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/cells12020239","article-title":"Effects of dupilumab on itch-related events in atopic dermatitis: implications for assessing treatment efficacy in clinical practice","volume":"12","author":"Kishi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.xjidi.2024.100258_bib27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xjidi.2024.100258_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cyto.2015.05.023","article-title":"Commentary: il-4 and IL-13 receptors and signaling","volume":"75","author":"McCormick","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.xjidi.2024.100258_bib29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the immune landscape in atopic dermatitis: the era of biologics and emerging therapeutic approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2024.100258_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100258_bib32","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1074\/jbc.M114.600973","article-title":"The S228P mutation prevents in\u00a0vivo and in\u00a0vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation","volume":"290","author":"Silva","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xjidi.2024.100258_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100258_bib35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100258_bib36","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1038\/s41598-018-25094-4","article-title":"IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity","volume":"8","author":"Takamori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2024.100258_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00403-004-0455-6","article-title":"Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis","volume":"295","author":"Tazawa","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xjidi.2024.100258_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib39","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1346-8138.1999.tb02090.x","article-title":"Itch and atopic dermatitis: an overview","volume":"26","author":"Wahlgren","year":"1999","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.xjidi.2024.100258_bib41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1165\/rcmb.2004-0128OC","article-title":"Upregulation of interleukin-4 receptor by interferon-gamma: enhanced interleukin-4-induced eotaxin-3 production in airway epithelium","volume":"31","author":"Yamamoto","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.xjidi.2024.100258_bib43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","article-title":"DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100258_bib44","article-title":"The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2024.100258_bib45","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/19420862.2019.1601985","article-title":"Important roles of CD32 in promoting suppression of IL-4 induced immune responses by a novel anti-IL-4R\u03b1 therapeutic antibody","volume":"11","author":"Zhao","year":"2019","journal-title":"mAbs"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:05:24Z","timestamp":1763021124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2667026724000043"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100258","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Bispecific, Tetravalent Antibody Targeting Inflammatory and Pruritogenic Pathways in Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100258"}}